Though the connection seems unusual, this news could change the lives of more than 700,000 Americans living with this disease ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

New vaccine to treat 15 types of cancer now available on NHS - New jab will treat skin, bladder and oesophagus cancer, with 1 ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Dr. Nicolas Soputro, a research fellow at the Cleveland Clinic, presented on the use of a robotic transurethral device for bladder tumor resection. He began by emphasizing that transurethral resection ...

ImmunityBio, Inc. faces stock decline amid fundraising and market selloff. Click to read more on the long-term potential of ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Laura Mertens, with a debate between Drs. Joshua Meeks and ...